Stockreport

Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting

SUNESIS PHARMACEUTICALS  (SNSS) 
Last sunesis pharmaceuticals earnings: 3/10 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.sunesis.com/investor-overview
PDF SOUTH SAN FRANCISCO, Calif., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of results from the Company [Read more]